Online inquiry

IVTScrip™ mRNA-Anti-SLC34A2, XMT-1536(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15890MR)

This product GTTS-WQ15890MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets SLC34A2 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_001300868.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3177
UniProt ID Q14542
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SLC34A2, XMT-1536(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ15890MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7552MR IVTScrip™ mRNA-Anti-GPC3, GC33(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA GC33
GTTS-WQ11516MR IVTScrip™ mRNA-Anti-FGFR3, MFGR1877S(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MFGR1877S
GTTS-WQ15007MR IVTScrip™ mRNA-Anti-CD19, SJ25C1 scFv-28Z CAR(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA SJ25C1 scFv-28Z CAR
GTTS-WQ14819MR IVTScrip™ mRNA-Anti-CD70, SGN-75(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA SGN-75
GTTS-WQ14499MR IVTScrip™ mRNA-Anti-CNR1, RYI-018(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA RYI-018
GTTS-WQ14001MR IVTScrip™ mRNA-Anti-GP, REGN-3470-3471-3479(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA REGN-3470-3471-3479
GTTS-WQ3163MR IVTScrip™ mRNA-Anti-O-antigen, AR-101(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AR-101
GTTS-WQ10994MR IVTScrip™ mRNA-Anti-CD79B, MCDS0593A(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MCDS0593A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW